Exercise of Options, Issue of Equity and TVR
14/03/2022 17:29
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220314:nRSN7384Ea&default-theme=true
RNS Number : 7384E Instem plc 14 March 2022
14 March 2022
Instem plc
("Instem" or "the Company")
Exercise of Options, Issue of Equity and Total Voting Rights
Instem plc (AIM: INS), a leading provider of IT solutions to the global life
sciences market, announces that it was notified on 14 March 2022 that certain
employees of the Company exercised share options ("Share Options") over, in
aggregate, 90,000 ordinary shares of 10 pence each in the Company ("Ordinary
Shares").
Issue of Equity and Admission
Application will be made to the London Stock Exchange for the admission of the
90,000 new Ordinary Shares to trading on AIM ("New Ordinary Shares").
Admission is expected to take place at 8.00 a.m. on 18 March 2022.
Total voting rights
Following the issue and allotment of the above New Ordinary Shares, the
Company's issued share capital comprises 22,379,856 Ordinary Shares. The
Company does not hold any Ordinary Shares in treasury. Therefore the total
number of voting rights in the Company is 22,379,856.
The figure of 22,379,856 may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change of their interest in, the Company under the
FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
Instem plc via Walbrook
Singer Capital Markets (Nominated Adviser & Broker) +44 (0) 20 7496 3000
Peter Steel
Rachel Hayes
Alex Bond
Stifel Nicolaus Europe Limited (Joint Broker) +44 (0) 20 7710 7600
Ben Maddison
Alex Price
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
About Instem
Instem is a leading provider of IT solutions & services to the life
sciences market delivering compelling solutions for Study Management,
Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based
Insight Generation.
Instem solutions are in use by over 700 customers worldwide, including all of
the largest 25 pharmaceutical companies, enabling clients to bring life
enhancing products to market faster. Instem's portfolio of software solutions
increases client productivity by automating study-related processes while
offering the unique ability to generate new knowledge through the extraction
and harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development
value chain, from discovery through to market launch. Management estimate that
over 50% of all drugs on the market have been through some part of Instem's
platform during their development.
To learn more about Instem solutions and its mission, please
visit www.instem.com (http://www.instem.com/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END TVRFLFFDVDISLIF